COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor

Junyang Li, Yali Zhou, Handong Wang, Yongyue Gao, Liwen Li, Sung Hee Hwang, Xiangjun Ji, Bruce D. Hammock

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: Cyclooxygenase-2 (COX-2)/soluble epoxide hydrolase (sEH) dual inhibitor, PTUPB, has been demonstrated to inhibit angiogenesis, primary tumor growth and metastasis. The aim of this study is to investigate the effects of PTUPB on glioblastoma cells and xenograft model. Results: We show here that PTUPB inhibits glioblastoma cell proliferation and G1 phase cell cycle arrest in vitro, and suppresses the tumor growth and angiogenesis in vivo. The expression and activation of epidermal growth factor receptor (EGFR) and its downstream kinases, ERK1/2 and AKT, are reduced by PTUPB, indicating that the EGF/ EGFR signaling pathway is a potential target. Moreover, PTUPB dramatically suppresses expression of hyaluronan mediated motility receptor (HMMR) in the glioblastoma cell lines and xenograft mouse model, suggesting that the HMMR is the other potential target. Materials and Methods: Cellular immunofluorescence assays were used for cell staining of actin fibers and HMMR. CCK-8 kit was used for cell proliferation assay. Cellcycle analysis was performed by flow cytometry. Quantitative real-time PCR assay was performed to test mRNA level. Western blot analysis was used to test protein expression. Immunohistochemical staining assay was used for xenograft tumor tissue staining of Ki-67, CD31 and HMMR. The SPSS version 17.0 software was applied for statistical analysis. Conclusions: Our data demonstrate that PTUPB is a potential therapeutic agent to treat glioblastomas.

Original languageEnglish (US)
Pages (from-to)87353-87363
Number of pages11
JournalOncotarget
Volume8
Issue number50
DOIs
StatePublished - 2017

Fingerprint

Epoxide Hydrolases
Cyclooxygenase 2
Glioblastoma
Epidermal Growth Factor Receptor
Heterografts
Staining and Labeling
Growth
Cell Proliferation
G1 Phase Cell Cycle Checkpoints
Sincalide
Neoplasms
Mitogen-Activated Protein Kinase 3
G1 Phase
Epidermal Growth Factor
Fluorescent Antibody Technique
Actins
Real-Time Polymerase Chain Reaction
Flow Cytometry
Software
Western Blotting

Keywords

  • Cyclooxygenase-2
  • Epidermal growth factor receptor
  • Glioblastoma
  • Hyaluronan mediated motility receptor
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Oncology

Cite this

COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor. / Li, Junyang; Zhou, Yali; Wang, Handong; Gao, Yongyue; Li, Liwen; Hwang, Sung Hee; Ji, Xiangjun; Hammock, Bruce D.

In: Oncotarget, Vol. 8, No. 50, 2017, p. 87353-87363.

Research output: Contribution to journalArticle

Li, Junyang ; Zhou, Yali ; Wang, Handong ; Gao, Yongyue ; Li, Liwen ; Hwang, Sung Hee ; Ji, Xiangjun ; Hammock, Bruce D. / COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor. In: Oncotarget. 2017 ; Vol. 8, No. 50. pp. 87353-87363.
@article{8bb62cb75d564de0ad60cc8fc2067fc8,
title = "COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor",
abstract = "Aims: Cyclooxygenase-2 (COX-2)/soluble epoxide hydrolase (sEH) dual inhibitor, PTUPB, has been demonstrated to inhibit angiogenesis, primary tumor growth and metastasis. The aim of this study is to investigate the effects of PTUPB on glioblastoma cells and xenograft model. Results: We show here that PTUPB inhibits glioblastoma cell proliferation and G1 phase cell cycle arrest in vitro, and suppresses the tumor growth and angiogenesis in vivo. The expression and activation of epidermal growth factor receptor (EGFR) and its downstream kinases, ERK1/2 and AKT, are reduced by PTUPB, indicating that the EGF/ EGFR signaling pathway is a potential target. Moreover, PTUPB dramatically suppresses expression of hyaluronan mediated motility receptor (HMMR) in the glioblastoma cell lines and xenograft mouse model, suggesting that the HMMR is the other potential target. Materials and Methods: Cellular immunofluorescence assays were used for cell staining of actin fibers and HMMR. CCK-8 kit was used for cell proliferation assay. Cellcycle analysis was performed by flow cytometry. Quantitative real-time PCR assay was performed to test mRNA level. Western blot analysis was used to test protein expression. Immunohistochemical staining assay was used for xenograft tumor tissue staining of Ki-67, CD31 and HMMR. The SPSS version 17.0 software was applied for statistical analysis. Conclusions: Our data demonstrate that PTUPB is a potential therapeutic agent to treat glioblastomas.",
keywords = "Cyclooxygenase-2, Epidermal growth factor receptor, Glioblastoma, Hyaluronan mediated motility receptor, Soluble epoxide hydrolase",
author = "Junyang Li and Yali Zhou and Handong Wang and Yongyue Gao and Liwen Li and Hwang, {Sung Hee} and Xiangjun Ji and Hammock, {Bruce D.}",
year = "2017",
doi = "10.18632/oncotarget.20928",
language = "English (US)",
volume = "8",
pages = "87353--87363",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

TY - JOUR

T1 - COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor

AU - Li, Junyang

AU - Zhou, Yali

AU - Wang, Handong

AU - Gao, Yongyue

AU - Li, Liwen

AU - Hwang, Sung Hee

AU - Ji, Xiangjun

AU - Hammock, Bruce D.

PY - 2017

Y1 - 2017

N2 - Aims: Cyclooxygenase-2 (COX-2)/soluble epoxide hydrolase (sEH) dual inhibitor, PTUPB, has been demonstrated to inhibit angiogenesis, primary tumor growth and metastasis. The aim of this study is to investigate the effects of PTUPB on glioblastoma cells and xenograft model. Results: We show here that PTUPB inhibits glioblastoma cell proliferation and G1 phase cell cycle arrest in vitro, and suppresses the tumor growth and angiogenesis in vivo. The expression and activation of epidermal growth factor receptor (EGFR) and its downstream kinases, ERK1/2 and AKT, are reduced by PTUPB, indicating that the EGF/ EGFR signaling pathway is a potential target. Moreover, PTUPB dramatically suppresses expression of hyaluronan mediated motility receptor (HMMR) in the glioblastoma cell lines and xenograft mouse model, suggesting that the HMMR is the other potential target. Materials and Methods: Cellular immunofluorescence assays were used for cell staining of actin fibers and HMMR. CCK-8 kit was used for cell proliferation assay. Cellcycle analysis was performed by flow cytometry. Quantitative real-time PCR assay was performed to test mRNA level. Western blot analysis was used to test protein expression. Immunohistochemical staining assay was used for xenograft tumor tissue staining of Ki-67, CD31 and HMMR. The SPSS version 17.0 software was applied for statistical analysis. Conclusions: Our data demonstrate that PTUPB is a potential therapeutic agent to treat glioblastomas.

AB - Aims: Cyclooxygenase-2 (COX-2)/soluble epoxide hydrolase (sEH) dual inhibitor, PTUPB, has been demonstrated to inhibit angiogenesis, primary tumor growth and metastasis. The aim of this study is to investigate the effects of PTUPB on glioblastoma cells and xenograft model. Results: We show here that PTUPB inhibits glioblastoma cell proliferation and G1 phase cell cycle arrest in vitro, and suppresses the tumor growth and angiogenesis in vivo. The expression and activation of epidermal growth factor receptor (EGFR) and its downstream kinases, ERK1/2 and AKT, are reduced by PTUPB, indicating that the EGF/ EGFR signaling pathway is a potential target. Moreover, PTUPB dramatically suppresses expression of hyaluronan mediated motility receptor (HMMR) in the glioblastoma cell lines and xenograft mouse model, suggesting that the HMMR is the other potential target. Materials and Methods: Cellular immunofluorescence assays were used for cell staining of actin fibers and HMMR. CCK-8 kit was used for cell proliferation assay. Cellcycle analysis was performed by flow cytometry. Quantitative real-time PCR assay was performed to test mRNA level. Western blot analysis was used to test protein expression. Immunohistochemical staining assay was used for xenograft tumor tissue staining of Ki-67, CD31 and HMMR. The SPSS version 17.0 software was applied for statistical analysis. Conclusions: Our data demonstrate that PTUPB is a potential therapeutic agent to treat glioblastomas.

KW - Cyclooxygenase-2

KW - Epidermal growth factor receptor

KW - Glioblastoma

KW - Hyaluronan mediated motility receptor

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=85031745547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031745547&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20928

DO - 10.18632/oncotarget.20928

M3 - Article

AN - SCOPUS:85031745547

VL - 8

SP - 87353

EP - 87363

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -